Glaucoma News and Research

Latest Glaucoma News and Research

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009

Blocking the dual leucine zipper kinase gene may help ease painful nerve condition

Scientists have identified the first gene that pulls the plug on ailing nerve cell branches from within the nerve cell, possibly helping to trigger the painful condition known as neuropathy.

15 Mar 2009

Experts discuss factors that may contribute to glaucoma

Although scientists know progressive degeneration of retinal ganglion cells and their axons is the primary cause of glaucoma, researchers have yet to identify a way to stop or prevent the degeneration.

4 Mar 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

Protease inhibitor found to aid diabetic retinopathy treatment

Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.

21 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

Glaucoma may be linked to reading impairment in older adults

Glaucoma appears to be associated with slower spoken reading and increased reading impairment in older adults, according to a report in the January issue of Archives of Ophthalmology.

12 Jan 2009

New cataract early detection device

A compact fiber-optic probe developed for the space program has now proven valuable for patients in the clinic as the first non-invasive early detection device for cataracts, the leading cause of vision loss worldwide.

8 Jan 2009

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001).

14 Dec 2008

Save money wih generics

Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings.

10 Dec 2008

Cases of major eye disease projected to increase among diabetics

Based on projected increases in the prevalence of diabetes, the number of people with diabetes-related retinal disease, with glaucoma and with cataracts is estimated to increase significantly by 2050, according to a report in the December issue of Archives of Ophthalmology.

8 Dec 2008

Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain.

30 Nov 2008

Surgical options for retinal detachment

Retinal detachment, a condition that afflicts about 10,000 Americans each year, puts an individual at risk for vision loss or blindness.

26 Nov 2008

Sleep disorders linked to eye disease

If a good night's sleep helps the brain and body perform better, it's a good guess that sleep problems can cause more than just fatigue.

11 Nov 2008

Sleep disorder linked to eye disease

Research has already suggested that sleep problems can cause more than just tiredness - they have been linked to cardiovascular disease, cerebrovascular disease and metabolic disorders, and are also thought to raise the risk of obesity and diabetes.

10 Nov 2008

Latest glaucoma research

Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.

10 Nov 2008